ImageneBio, Inc. (IMA)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
5.34 USD
+0.01
(0.188%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.33 |
Hot Take ↕ | Aug. 22, 2026, 3:58 a.m. EDT
The immediate outlook is severely clouded by aggressive insider selling, with the principal accounting officer and chief selling significant stakes while the stock dips, signaling deep internal skepticism about the company's path forward. While the balance sheet currently boasts a fortress-like liquidity position with massive cash reserves relative to debt, this is a temporary reprieve for a biotech firm burning through capital at an alarming rate, evidenced by substantial negative free cash flow and operating cash flows. The long-term investment case is fundamentally broken; the business has suffered a catastrophic collapse in value, losing nearly 90% of its worth over the last four years, with the most recent annual performance showing another sharp decline. This multi-year trajectory of destruction suggests the market has correctly identified a deteriorating business model rather than a value opportunity. With no dividend to provide income and a lack of sustainable profitability, the security represents a high-risk speculative bet on a turnaround that the insiders themselves appear to doubt. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.032423 |
| AutoETS | 0.033996 |
| AutoTheta | 0.034771 |
| MSTL | 0.039935 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.202 |
| Excess Kurtosis | -1.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.346 |
| Market Cap | 60,616,776 |
| Forward P/E | -1.24 |
| Previous Name | Inmagene Biopharmaceuticals Co. Ltd. |
| Website | https://www.inmagenebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6010479 |
| Address1 | 12,526 High Bluff Drive |
| Address2 | Suite 345 |
| All Time High | 451.32 |
| All Time Low | 3.94 |
| Ask | 5.39 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 10,510 |
| Average Daily Volume3 Month | 11,962 |
| Average Volume | 11,962 |
| Average Volume10Days | 10,510 |
| Bid | 3.78 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 12.596 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.34 |
| Current Ratio | 21.468 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.35 |
| Day Low | 5.32 |
| Debt To Equity | 1.346 |
| Display Name | ImageneBio |
| Ebitda | -58,366,500 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.261 |
| Enterprise Value | -73,624,224 |
| Eps Current Year | -3.31 |
| Eps Forward | -4.31 |
| Eps Trailing Twelve Months | -4.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7737 |
| Fifty Day Average Change | -0.43370008 |
| Fifty Day Average Change Percent | -0.075116485 |
| Fifty Two Week Change Percent | -60.104786 |
| Fifty Two Week High | 13.98 |
| Fifty Two Week High Change | -8.639999 |
| Fifty Two Week High Change Percent | -0.6180257 |
| Fifty Two Week Low | 3.94 |
| Fifty Two Week Low Change | 1.4000001 |
| Fifty Two Week Low Change Percent | 0.35532996 |
| Fifty Two Week Range | 3.94 - 13.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,765,400,000 |
| Float Shares | 5,846,567 |
| Forward Eps | -4.31 |
| Forward P E | -1.2389792 |
| Free Cashflow | -23,211,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Fullday Change | 0.0100002 |
| Fullday Change Percent | 0.187622 |
| Fullday Price | 5.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15702 |
| Held Percent Institutions | 0.54495 |
| Implied Shares Outstanding | 11,351,456 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,660,800 |
| Last Split Factor | 1:12 |
| Long Business Summary | ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. |
| Long Name | ImageneBio, Inc. |
| Market | us_market |
| Market Cap | 60,616,776 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_689254445 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -53,330,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 60,503,260 |
| Number Of Analyst Opinions | 3 |
| Open | 5.35 |
| Operating Cashflow | -52,586,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 345 6265 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.33 |
| Post Market Time | 1,787,947,804 |
| Prev Name | Inmagene Biopharmaceuticals Co. Ltd. |
| Previous Close | 5.33 |
| Price Eps Current Year | -1.6132932 |
| Price Hint | 2 |
| Price To Book | 0.42394415 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 20.714 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.010000229 |
| Regular Market Change Percent | 0.18762156 |
| Regular Market Day High | 5.35 |
| Regular Market Day Low | 5.32 |
| Regular Market Day Range | 5.32 - 5.35 |
| Regular Market Open | 5.35 |
| Regular Market Previous Close | 5.33 |
| Regular Market Price | 5.34 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 4,509 |
| Return On Assets | -0.43057 |
| Return On Equity | -0.82677 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 11,351,456 |
| Shares Percent Shares Out | 0.0043 |
| Shares Short | 49,297 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 393,691 |
| Short Name | ImageneBio, Inc. |
| Short Percent Of Float | 0.0044 |
| Short Ratio | 4.47 |
| Source Interval | 15 |
| State | CA |
| Symbol | IMA |
| Target High Price | 28.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 18.0 |
| Target Median Price | 24.0 |
| Total Cash | 136,152,992 |
| Total Cash Per Share | 11.994 |
| Total Debt | 1,912,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.14026 |
| Two Hundred Day Average Change | -0.80026007 |
| Two Hundred Day Average Change Percent | -0.13033 |
| Type Disp | Equity |
| Volume | 4,509 |
| Website | https://www.inmagenebio.com |
| Zip | 92,130 |